biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Webinar Rerun

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jun 23, 2022 6:48am

154 Views

Post# 34776226

RE:RE:The Webinar Rerun

KayakerBC wrote: Listening to the Webinar question (39:25) re listing on the Nasdaq. As DrDR indicates, it would be "American depositary shares" (ADS) that trade on the NASDAQ. I don't claim to have a great understanding of it, but it looks like each ADS would represent a "bundle" of BTI shares, so that the price meets NASDAQ requirements.

So, I assume we would keep our shares in our "underlying exchange", though it seems they could be exchanged for ADS. (AstraZeneca and Novartis are examples of companies that trade as ADS on US exchanges.) I assume, of course, there will be dilution at the IPO. In the prior question, DrDR was still showing sensitivity to not "unduly" diluting shareholders. Here is a decent article on ADRs and ADS on the NASDAQ.

KBC I am not sure this is the best way to get BTI trading on the Nasdaq. As there will be a certain conversion ratio ( a number of ADSs bunched into one ADR) to meet the requirement of the Nasdaq around the price, I see no difference from going the reverse stock split to attain a share price to meet Nasdaq.

The name Lambert Thalman (if I understood the name correctly) will undertake the ADR/ADS stock transformation.

You stated the following " I assume, of course, there will be dilution at the IPO.". Why is an IPO required?

So if I understand this correctly here in Canada BTI continues to trade on the Venture exchange at the current share price ( today being 18 cents) and in the US it will trade as an ADR which could end up 30 X 18 cents ($5.40) in US dollars through a U.S. Depository Bank and is available for purchase by U. S. investors.

I may have all of this wrong, so please do your own DD.

JMO
G1945V

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!